BioSpace News Archive

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, President and Chief Executive Officer, will make a corporate presentation at the LifeSci Partners 10 th Annual Healthcare Corporate Access Event, on Thursday, January 7, 2021 at 11am Eastern Time . Anticipating the launch in 1Q21

Yuyu Pharma received recognition from the Ministry of Gender Equality and Family for implementing family-friendly policies for their employees.

Health Canada is aware that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued an authorization for a COVID-19 vaccine manufactured by AstraZeneca.

Moderna, Inc. (NASDAQ:MRNA), biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO), today announced that they have reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S.

TheraCell Inc., a leading allograft solution company, today announced that it has completed the first surgical case using its TheraFuze DBF® Fiber Bullets™.

Women who develop high blood pressure during pregnancy may be more likely to have lower scores on tests of memory and thinking skills 15 years later than women who did not develop high blood pressure during pregnancy, according to a new study published in the December 30, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Walgreens Boots Alliance, Inc. announced that Co-Chief Operating Officer Alex Gourlay and Executive Vice President and Global Chief Financial Officer James Kehoe will participate at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13 at 11:40 a.m. Eastern time.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the First Quarter of Fiscal 2021 on Thursday, February 4, 2021, prior to the opening of trading on the New York Stock Exchange.

Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Proenzymes Optimization Project 1 (“POP1”) joint research and drug discovery program advanced towards producing commercial scale quantities of the two proenzymes trypsinogen and chymotrypsinogen. The

WUHAN GENERAL GROUP, INC., a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update: